Cargando…

When the Good Syndrome Goes Bad: A Systematic Literature Review

BACKGROUND: Good syndrome is a rare adult-onset immunodeficiency characterized by thymoma and hypogammaglobulinemia. Its clinical manifestations are highly heterogeneous, ranging from various infections to autoimmunity. OBJECTIVE: This study was to summarize patient characteristics, identify prognos...

Descripción completa

Detalles Bibliográficos
Autores principales: Shi, Yiyun, Wang, Chen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8185358/
https://www.ncbi.nlm.nih.gov/pubmed/34113351
http://dx.doi.org/10.3389/fimmu.2021.679556
_version_ 1783704774714064896
author Shi, Yiyun
Wang, Chen
author_facet Shi, Yiyun
Wang, Chen
author_sort Shi, Yiyun
collection PubMed
description BACKGROUND: Good syndrome is a rare adult-onset immunodeficiency characterized by thymoma and hypogammaglobulinemia. Its clinical manifestations are highly heterogeneous, ranging from various infections to autoimmunity. OBJECTIVE: This study was to summarize patient characteristics, identify prognostic factors and define clinical subgroups of Good syndrome. METHODS: A systematic literature review was conducted to include patients with Good syndrome identified in PubMed, Embase and Cochrane databases between January 2010 and November 2020. Logistic and Cox regressions were used to identify prognostic factors impacting outcomes. Clinical subgroups were defined by multiple correspondence analysis and unsupervised hierarchical clustering. A decision tree was constructed to characterize the subgroup placement of cases. RESULTS: Of 162 patients included in the current study, the median age at diagnosis was 58 years and 51% were male. Type AB was the most common histological subtype of thymoma, and infections as well as concurrent autoimmune disorders were identified in 92.6% and 51.2% patients, respectively. Laboratory workup showed typical findings of combined immunodeficiency. Thymoma status (odds ratio [OR] 4.157, confidence interval [CI] 1.219-14.177, p = 0.023), infections related to cellular immunity defects (OR 3.324, 95% CI 1.100-10.046, p = 0.033), infections of sinopulmonary tract (OR 14.351, 95% CI 2.525-81.576, p = 0.003), central nerve system (OR 6.403, 95% CI 1.205-34.027, p = 0.029) as well as bloodstream (OR 6.917, 95% CI 1.519-31.505, p = 0.012) were independent prognostic factors. The 10-year overall survival was 53.7%. Cluster analysis revealed three clinical subgroups with distinct characteristics and prognosis (cluster 1, infections related to cellular immunity defects; cluster 2, infections related to other immunity defects; cluster 3, infections related to humoral and phagocytic immunity defects). A decision tree using infection types (related to humoral and cellular immunity defects) could place patients into corresponding clusters with an overall correct prediction of 72.2%. CONCLUSIONS: Infection type and site were the main prognostic factors impacting survival of patients with Good syndrome. We identified three subgroups within Good syndrome associated with distinct clinical features, which may facilitate the study of underlying pathogenesis as well as development of targeted therapy.
format Online
Article
Text
id pubmed-8185358
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-81853582021-06-09 When the Good Syndrome Goes Bad: A Systematic Literature Review Shi, Yiyun Wang, Chen Front Immunol Immunology BACKGROUND: Good syndrome is a rare adult-onset immunodeficiency characterized by thymoma and hypogammaglobulinemia. Its clinical manifestations are highly heterogeneous, ranging from various infections to autoimmunity. OBJECTIVE: This study was to summarize patient characteristics, identify prognostic factors and define clinical subgroups of Good syndrome. METHODS: A systematic literature review was conducted to include patients with Good syndrome identified in PubMed, Embase and Cochrane databases between January 2010 and November 2020. Logistic and Cox regressions were used to identify prognostic factors impacting outcomes. Clinical subgroups were defined by multiple correspondence analysis and unsupervised hierarchical clustering. A decision tree was constructed to characterize the subgroup placement of cases. RESULTS: Of 162 patients included in the current study, the median age at diagnosis was 58 years and 51% were male. Type AB was the most common histological subtype of thymoma, and infections as well as concurrent autoimmune disorders were identified in 92.6% and 51.2% patients, respectively. Laboratory workup showed typical findings of combined immunodeficiency. Thymoma status (odds ratio [OR] 4.157, confidence interval [CI] 1.219-14.177, p = 0.023), infections related to cellular immunity defects (OR 3.324, 95% CI 1.100-10.046, p = 0.033), infections of sinopulmonary tract (OR 14.351, 95% CI 2.525-81.576, p = 0.003), central nerve system (OR 6.403, 95% CI 1.205-34.027, p = 0.029) as well as bloodstream (OR 6.917, 95% CI 1.519-31.505, p = 0.012) were independent prognostic factors. The 10-year overall survival was 53.7%. Cluster analysis revealed three clinical subgroups with distinct characteristics and prognosis (cluster 1, infections related to cellular immunity defects; cluster 2, infections related to other immunity defects; cluster 3, infections related to humoral and phagocytic immunity defects). A decision tree using infection types (related to humoral and cellular immunity defects) could place patients into corresponding clusters with an overall correct prediction of 72.2%. CONCLUSIONS: Infection type and site were the main prognostic factors impacting survival of patients with Good syndrome. We identified three subgroups within Good syndrome associated with distinct clinical features, which may facilitate the study of underlying pathogenesis as well as development of targeted therapy. Frontiers Media S.A. 2021-05-25 /pmc/articles/PMC8185358/ /pubmed/34113351 http://dx.doi.org/10.3389/fimmu.2021.679556 Text en Copyright © 2021 Shi and Wang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Shi, Yiyun
Wang, Chen
When the Good Syndrome Goes Bad: A Systematic Literature Review
title When the Good Syndrome Goes Bad: A Systematic Literature Review
title_full When the Good Syndrome Goes Bad: A Systematic Literature Review
title_fullStr When the Good Syndrome Goes Bad: A Systematic Literature Review
title_full_unstemmed When the Good Syndrome Goes Bad: A Systematic Literature Review
title_short When the Good Syndrome Goes Bad: A Systematic Literature Review
title_sort when the good syndrome goes bad: a systematic literature review
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8185358/
https://www.ncbi.nlm.nih.gov/pubmed/34113351
http://dx.doi.org/10.3389/fimmu.2021.679556
work_keys_str_mv AT shiyiyun whenthegoodsyndromegoesbadasystematicliteraturereview
AT wangchen whenthegoodsyndromegoesbadasystematicliteraturereview